About the Global Campaign
In countries from the U.S. to Vietnam, Brazil to Indonesia, health groups are aiming to break Abbott’s monopoly control over lopinavir+ritonavir (Kaletra). Campaigners say Abbott’s high price for Kaletra is blocking expansion of AIDS treatment, and its anti-competitive practices are impeding new drug innovation.
PRESS RELEASE (November 9, 2011)
English | Español | Chinese
Return to the Kaletra Campaign Homepage